According to the different OCT characteristics, DME is mainly classified into diffuse retinal thickening (DRT), cystoid macular edema (CME), and serous retinal detachment (SRD).[9] It has been identified that the efficacy and prognosis of anti-VEGF drugs vary among different types of DME patients.[10] At present, most contemporary research studies have focused on anti-VEGF drugs such as bevacizumab and ranibizumab. The gene discussed is VEGFA; the disease is Cystoid macular dystrophy.